A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2004
11/24/2004	CN1176661C Gene medicine against mammitis of dairy cow
11/23/2004	US6822087 For anti-asthma/allergy/hypereosinophilia/inflammation/ cancer/tumor drugs; gene expression inhibition
11/23/2004	US6821957 Vectors containing neutralizing motifs and/or a reduced number of immunostimulatory cpg motifs and methods of use for gene therapy protocols
11/23/2004	US6821956 Oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes.
11/23/2004	US6821948 Conjugate for mediating cell, compartment or membrane-specific transport of active substances
11/23/2004	US6821946 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves
11/23/2004	US6821945 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
11/23/2004	US6821777 Cell line preparing and producing ovine adenovirus vectors
11/23/2004	US6821775 Viral vector encoding pigment epithelium-derived factor
11/23/2004	US6821754 Staphylococcus aureus genes and polypeptides
11/23/2004	US6821753 Replication incompetent herpes viruses for use in gene therapy
11/23/2004	US6821745 Regulation of human pyroglutamyl peptidase-like enzyme
11/23/2004	US6821731 Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
11/23/2004	US6821519 Comprises polypeptide for detecting viral infection; immunoassays; immunostimulant
11/23/2004	US6821512 Selective packaging of the adenovirus (ad) genome into viral capsids
11/23/2004	US6821511 Transducing cell; incubate cells with nucleotide sequences, insert cells into mammals, monitor mammals for phenotypic adjustment
11/23/2004	US6821264 Transduction efficiency; localizing and increasing uptake of vector at tissue site
11/23/2004	CA2242035C Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
11/23/2004	CA2012482C Hepatitis c diagnostics and vaccines
11/22/2004	CA2441681A1 Cancer monitoring and therapeutics
11/18/2004	WO2004099423A1 Vp2-modified raav vectors and uses thereof
11/18/2004	WO2004099422A2 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
11/18/2004	WO2004099387A2 siRNA INDUCED SYSTEMIC GENE SILENCING IN MAMMALIAN SYSTEMS
11/18/2004	WO2004099377A2 An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
11/18/2004	WO2004099363A2 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	WO2004098648A1 Gene therapy for neurometabolic disorders
11/18/2004	WO2004098647A2 Claudins’ underexpression as markers of tumor metastasis
11/18/2004	WO2004098646A1 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
11/18/2004	WO2004098534A2 Methods for delivering angiogenic modulators using pox viruses
11/18/2004	WO2004098531A2 Increased transduction using abc transporter substrates and/or inhibitors
11/18/2004	WO2004098526A2 Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
11/18/2004	WO2004098509A2 Compositions for inducing immune responses
11/18/2004	WO2004098508A2 Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
11/18/2004	WO2004098499A2 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
11/18/2004	WO2004098491A2 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
11/18/2004	WO2004098490A2 Mesoderm and definitive endoderm cell populations
11/18/2004	WO2004090133A3 Method of rna cleavage and recombination
11/18/2004	WO2004087930A8 Adenovirus replication-competent vectors expressing trail
11/18/2004	WO2004087752A3 Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
11/18/2004	WO2004084951A3 A method and vectors for selectively transducing retinal pigment epithelium cells
11/18/2004	WO2004082573A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
11/18/2004	WO2004060476A3 Wound healing method and kits
11/18/2004	WO2004048591A3 Methods for cohort selection and longevity studies
11/18/2004	WO2004043353A3 Compositions and methods for treating acute myeloid leukemia
11/18/2004	WO2004038406A3 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
11/18/2004	WO2004000164A3 Amniotic membrane mediated delivery of bioactive molecules
11/18/2004	WO2003087021A8 Nanoparticle delivery systems and methods of use thereof
11/18/2004	WO2003076591A8 Compositions and methods for generating an immune response
11/18/2004	WO2002090499A3 ss-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME
11/18/2004	US20040231009 Using variation in sensory organ developmental genes to diagnose and treat nervous system disorders; tissue engineering and gene therapy
11/18/2004	US20040231006 Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
11/18/2004	US20040231005 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases
11/18/2004	US20040230043 Novel neurotrophic factors
11/18/2004	US20040230039 Nucleotide sequences coding interleukin-1b converting enzyme comprising death domains for identifying modulators of fatty acid synthase and treatment of cachexia, viral infection and cell proliferative disorders
11/18/2004	US20040229842 Use of lipid conjugates in the treatment of diseases
11/18/2004	US20040229835 Immunostimulatory nucleic acid molecules
11/18/2004	US20040229833 Therapeutic use of cis-element decays in vivo
11/18/2004	US20040229831 Compositions and methods for non-parenteral delivery of oligonucleotides
11/18/2004	US20040229828 Administering a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length
11/18/2004	US20040229806 Hirulog-like peptide and gene therapy
11/18/2004	US20040229804 Tribonectins
11/18/2004	US20040229792 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
11/18/2004	US20040229779 NOVX nucleic acids and their encoded polypeptides; diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers.
11/18/2004	US20040229362 Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
11/18/2004	US20040229361 Mammalian cell line for use as tool in preparation of gene transfer sequences; tissue engineering; bioreactor for production of therapeutic proteins
11/18/2004	US20040229358 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
11/18/2004	US20040229339 Comprises neisseria membrane protein for use as tool in generation of vaccine to prevent infection and sepsis in infants
11/18/2004	US20040229338 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/18/2004	US20040229275 Comprises nucleotide sequences coding membrane transport protein for use in identifying modulators for treatment of low high density lipoprotein concentration, high triglyceride levels and/or cardiovascular disorders
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040229260 Comprises nucleotide sequences coding interleukin-1b converting enzyme ligand for use in diagnosis, prevention and treatment of autoimmune, connective tissue and crohn's diseases
11/18/2004	US20040228920 HoxD3, HoxA3, and HoxB3 compositions and methods for improved wound healing
11/18/2004	US20040228881 Compositions and methods for modulating neural sprouting
11/18/2004	US20040228866 Suppressor genes
11/18/2004	US20040228860 Antibodies to a tumor-associated surface antigen for delivery of diagnostic and therapeutic agents
11/18/2004	US20040228843 Preparing chimeric expression vector for use as gene transfer tool in heterologous gene expression; tissue engineering
11/18/2004	US20040228842 Compositions and methods for cytomegalovirus treatment
11/18/2004	US20040228841 Replication-competent herpes simplex virus mediates destruction of neoplastic cells
11/18/2004	CA2788000A1 Apparatus for harvesting a dermal micro-organ
11/18/2004	CA2748670A1 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	CA2748661A1 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	CA2748659A1 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	CA2684022A1 Mesoderm and definitive endoderm cell populations
11/18/2004	CA2524912A1 An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
11/18/2004	CA2524623A1 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
11/18/2004	CA2524217A1 Compositions for inducing immune responses
11/18/2004	CA2524172A1 Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
11/18/2004	CA2524063A1 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
11/18/2004	CA2523870A1 Claudins' underexpression as markers of tumor metastasis
11/18/2004	CA2523706A1 Dermal micro organs, methods and apparatuses for producing and using the same
11/18/2004	CA2519680A1 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
11/18/2004	CA2504493A1 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
11/18/2004	CA2500523A1 Vp2-modified raav vector compositions and uses therefor
11/18/2004	CA2487058A1 Mesoderm and definitive endoderm cell populations
11/17/2004	WO2004107200A1 System and method for controlling user interface properties with data
11/17/2004	EP1477564A2 Human synthetases
11/17/2004	EP1476581A2 Recombinant bovine immunodeficiency virus based gene transfer system
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476564A1 Cooperative oligonucleotides
11/17/2004	EP1476553A2 Gene for peripheral arterial occlusive disease

1 ... 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 ... 870